Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
Saved in:
| Title: | Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. |
|---|---|
| Authors: | Atreya, Raja1 (AUTHOR), Ferrante, Marc2 (AUTHOR), Panaccione, Remo3 (AUTHOR), Feagan, Brian4 (AUTHOR), Shchukina, Oksana5 (AUTHOR), Jairath, Vipul4 (AUTHOR), Rieder, Florian6 (AUTHOR), Hisamatsu, Tadakazu7 (AUTHOR), Siegmund, Britta8 (AUTHOR), Kligys, Kristina9 (AUTHOR), Song, Alexandra9 (AUTHOR), Zambrano, Javier9 (AUTHOR), Mallick, Madhuja9 (AUTHOR), Zhang, Yafei9 (AUTHOR), Armuzzi, Alessandro10,11 (AUTHOR), D'Haens, Geert12 (AUTHOR) |
| Source: | Journal of Crohn's & Colitis. Apr2025, Vol. 19 Issue 4, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
